0001209191-19-053739.txt : 20191021
0001209191-19-053739.hdr.sgml : 20191021
20191021193146
ACCESSION NUMBER: 0001209191-19-053739
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191017
FILED AS OF DATE: 20191021
DATE AS OF CHANGE: 20191021
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leber Laura
CENTRAL INDEX KEY: 0001649191
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51541
FILM NUMBER: 191160415
MAIL ADDRESS:
STREET 1: C/O GENOMIC HEALTH, INC.
STREET 2: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOMIC HEALTH INC
CENTRAL INDEX KEY: 0001131324
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 770552594
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-556-9300
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-10-17
0
0001131324
GENOMIC HEALTH INC
GHDX
0001649191
Leber Laura
301 PENOBSCOT DR.
REDWOOD CITY
CA
94063
0
1
0
0
Chief Communication Officer
Common Stock
2019-03-11
5
G
0
E
275
0.00
D
13420
D
Common Stock
2019-10-17
4
M
0
13183
22.98
A
26919
D
Common Stock
2019-10-17
4
S
0
13183
70.942
D
13736
D
Employee Stock Option (right to buy)
22.98
2019-10-17
4
M
0
13183
0.00
D
2021-01-27
Common Stock
13183
0
D
Includes an aggregate of 9,384 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 14, 2018.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $70.71 to $71.135.
The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
/s/ Jason W. Radford, Attorney-in-fact
2019-10-21